Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 3Active not recruiting 3Withdrawn 1Terminated 1Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3Breast 3Thoracic 2Gynecologic 2Gastrointestinal 2Sarcoma 1

Conditions

Breast Neoplasms 55Neoplasm Metastasis 5Triple Negative Breast Neoplasms 3Prostatic Neoplasms 3Ovarian Neoplasms 3Uterine Neoplasms 2Uterine Cervical Neoplasms 2Small Cell Lung Carcinoma 2Recurrence 2Endometrial Neoplasms 2Colorectal Neoplasms 2Urologic Neoplasms 1Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Neoplasms by Site 1Neoplasms 1Malignant Neoplasms of Female Genital Organs 1Locally Advanced (Inoperable) or Metastatic Breast Cancer 1Liposarcoma 1Hormone Receptor Positive Breast Carcinoma 1Head and Neck Neoplasms 1HR-positive, HER2-negative Breast Neoplasms 1HER2-positive Metastatic Breast Cancer 1Genital Neoplasms, Female 1Genetic Diseases, Inborn 1Estrogen Receptor Positive Breast Cancer 1ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer 1Disease Progression 1

Interventions

enzalutamide 33Abiraterone Acetate 28apalutamide 25Radiotherapy 25Prednisone 25Magnetic Resonance Spectroscopy 25Androgen Antagonists 24Leuprolide 21Radiosurgery 19darolutamide 18Docetaxel 17acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 15Gonadotropin-Releasing Hormone 14gallium 68 PSMA-11 12Specimen Handling 12Goserelin 12pembrolizumab 11Radiotherapy, Intensity-Modulated 11Radiation 11bicalutamide 10abiraterone 10Pluvicto 10Carboplatin 9Brachytherapy 92-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 9relugolix 8luprolide acetate gel depot 8Standard of Care 8Nivolumab 8olaparib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Prostatic Neoplasms × Fulvestrant × Clear all
NCT06257264 2026-06-05

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

BeOne Medicines

Phase 1 Active not recruiting
103 enrolled
BreastGastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT07038369 2026-06-03

A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations

Atavistik Bio, Inc

Phase 1 Active not recruiting
134 enrolled
BreastGenitourinaryGynecologic

Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Genital Neoplasms, Female, Neoplasms, Neoplasms by Site, Ovarian Neoplasms, Prostatic Neoplasms, Urogenital Neoplasms, Uterine Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04557449 2025-10-01

CDK4i

Pfizer

Phase 2 Active not recruiting
362 enrolled
BreastGastrointestinalGenitourinarySarcomaThoracic

Adenocarcinoma of Lung, Breast Neoplasms, Liposarcoma, Prostatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡